Vaccitech prices shares at $17 for U.S. IPO
Tweet
Share
E-mail
FILE PHOTO: Vials of Oxford/AstraZeneca's COVID-19 vaccine are pictured at a vaccination centre in Bierset, Belgium March 17, 2021. REUTERS/Yves Herman
(Reuters) - Vaccitech Plc, the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial public offering.
The British company expects gross proceeds of $110.5 million from the offering of 6.5 mln of its American Depositary Shares (ADSs), representing the same number of ordinary shares.
Vaccitech had announced its plans to go public earlier this month and said the ADSs would begin trading on the Nasdaq under the symbol "VACC" on April 30.
Its preference for a U.S. listing to one in the UK could further undermine London's attempts to become a major financial hub, particularly after Brexit.
The company expects the offering to close on May 4.
Morgan Stanley, Jefferies, Barclays and William Blair are acting as bookrunners for the offering. H.C. Wainwright & Co is acting as the lead manager for the offering.
(Reporting by Trisha Roy in Bengaluru; Editing by Subhranshu Sahu)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Q32 Bio launches $200M stock offering to fund clinical trials
- Chip toolmaker ASML expected to shine light on capacity and China challenges
- Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
Create E-mail Alert Related Categories
ReutersRelated Entities
William Blair, Morgan Stanley, Jefferies & Co, Barclays, IPO, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
